Q-omics provides the consensus-scored MEAK7 profile across patient tissues and cancer cell-line models. MEAK7 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MEAK7 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, MEAK7 protein abundance shows 20,218 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight ACC, and HNSC as cancer lineages where MEAK7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MEAK7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MEAK7 survival associations across molecular data types. MEAK7 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MEAK7 RNA expression–survival associations across cancer types. High MEAK7 expression shows unfavorable associations in ACC, LUAD, HNSC, PAAD, BRCA and LIHC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MEAK7 RNA expression.
This table summarizes MEAK7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for MEAK7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MEAK7 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRP, LUAD, LIHC and LUSC. The HNSC box plot shows higher MEAK7 RNA expression in tumor versus normal tissue (log2 FC = +1.815, t-test p < 0.001).
This table shows molecular features associated with MEAK7 in patient tissues and cancer cell lines. In patient samples, MEAK7 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, MEAK7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and CNS.
